Accelerating analysis of viral vector titer, process impurities, and contaminants

 John Chappell has approximately 25 years of experience in the Contract Research industry supporting both preclinical and clinical drug development. He has specialized in supporting biological compounds from an analytical perspective e.g. Pharmacokinetic, Immunogenicity and Biomarker analysis. He is particularly interested in validation requirements and ensuring that data generated will be acceptable to the regulatory authorities.

He has spoken at many international conferences on various topics including Oligonucleotide analysis, Biomarker Analysis, Immunogenicity and the analytical support of Biosimilar programs. He now leads the Application Support and Service teams for Gyros where he is responsible for customer service and technical support in Europe and the Asia Pacific regions. John has been a user of the Gyros system for over 10 years so will use this experience to help customers.

He is a Fellow of the Royal Society of Chemistry and was involved in the American Association of Pharmaceutical Scientists (AAPS) Biosimilar Committee that has prepared papers on Pharmacokinetic and anti-drug antibody assays.

James Norton, works at MeiraGTx as Director of Analytical Development. James joined MeiraGTx in 2018 and has held different roles including Head of Quality Control. Prior to joining MeiraGTx James worked in a variety of roles within the pharmaceutical industry and has gained extensive experience in GMP/GLP quality release and stability testing, as well as analytical method development and validation across Biotech, Small molecule and ATMP’s.

In his current role as Director of Analytical Development at MeiraGTx James leads the R&D department providing analytical services for AAV gene therapy in ophthalmology, salivary gland, and neurodegenerative diseases.

Barbara Rodriguez holds a MSc in Applied Chemistry and Polymers from the University of the Basque Country, and Doctor in Biomedical Biotechnology from the University of Barcelona.

She began her research activity in the field of nanobiotechnology followed by specializing in the development of immunoassays based on the detection of biomarkers related to infectious diseases.

Bárbara joined VIVEbiotech, a CDMO specialized in the manufacturing of lentiviral vectors, in early 2022 and holds a position as Analytical Development Scientist in the Quality Control Department.